Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03555851 · ClinicalTrials.gov registry record

Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy

A clinical trial of Leukemia, Other and Leukemia, Not Otherwise Specified, sponsored by Wake Forest University Health Sciences.

Recruiting
Registry status
120
Enrollment target
1
Study location

NCT03555851 is a study of Leukemia, Other and Leukemia, Not Otherwise Specified that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 120 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03555851, a study of Leukemia, Other and Leukemia, Not Otherwise Specified, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.

RECRUITING
Registry status
120 participants
Enrollment target
1
Study location

Study Summary

This study will examine the influence of donor and recipient pharmacogenetics (PG), drug pharmacokinetics (PK), and T cell phenotypes and how it may permit a tailored dosing strategy to improve the therapeutic index of post-transplant cyclophosphamide (PTCy) and optimize the graft versus tumor effect, while minimizing acute and chronic graft versus host disease (GVHD).

Interventions

  • DRUG Cyclophosphamide
  • OTHER Specimen collection

Study Locations (1)

North Carolina

  • Levine Cancer Institute - Charlotte

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2018-07-13
Est. Completion 2035-08

Sponsor

Wake Forest University Health Sciences

1,140 total trials

What the Registry Record Tells You About NCT03555851

The ClinicalTrials.gov registry entry for NCT03555851 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Leukemia, Other appearing as the primary indexed condition, and to 2 interventions - of which Cyclophosphamide is the first listed.

NCT03555851 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT03555851 about?

NCT03555851 is a clinical study titled "Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy". This study will examine the influence of donor and recipient pharmacogenetics (PG), drug pharmacokinetics (PK), and T cell phenotypes and how it may permit a tailored dosing strategy to improve the therapeutic index of post-transplant cyclophosphamide (PTCy) and optimize the graft versus tumor effec...

What is the current status of trial NCT03555851?

This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2018-07-13. Estimated completion is 2035-08.

What conditions does trial NCT03555851 study?

This clinical trial studies the following conditions: Leukemia, Other, Leukemia, Not Otherwise Specified.

What interventions are being tested in trial NCT03555851?

The interventions under investigation include: Cyclophosphamide (DRUG), Specimen collection (OTHER).

Who is sponsoring clinical trial NCT03555851?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03555851 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Leukemia, Other

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.